Optiscan Completes MVP for Secure, Real-Time Telepathology Streaming Software

Breaking New Ground in Digital Pathology

Optiscan Imaging Ltd (ASX:OIL) has announced a significant advancement in digital healthcare technology with the successful completion of the Minimum Viable Product (MVP) for its cloud-based telepathology streaming software. Developed in partnership with Canadian software firm Prolucid Technologies, this milestone marks a transformative step toward enabling pathologists and clinicians to collaborate remotely in real time, overcoming traditional geographic and infrastructure barriers.

The software platform integrates seamlessly with Optiscan’s suite of proprietary medical devices, including InVue®, InForm, and InVivage®, allowing high-resolution microscopic images to be streamed securely over the cloud. This capability empowers pathologists to review live imaging sessions, annotate images, generate reports, and consult with clinicians regardless of their physical location, effectively bringing expert pathology insights directly to the point of care.

Security and Usability at the Forefront

Data privacy and security have been central to the platform’s design. The system employs robust encryption, secure logins, and strict access controls to protect patient confidentiality. Notably, patient-identifiable information is never transferred through the cloud; instead, images are anonymized by default and stored securely, with personal data retained only locally on devices. The platform also supports multi-user sessions, enabling synchronous consultations and asynchronous report generation, which aligns with the collaborative nature of pathology practice.

Technologically, the platform leverages WebRTC protocol to ensure low latency streaming, typically under half a second, facilitating near real-time interaction. This responsiveness is critical in clinical environments where timely decisions can impact patient outcomes. The ability to invite external specialists for second opinions further enhances the platform’s utility and reflects a modern approach to multidisciplinary care.

Looking Ahead: Validation and Deployment

With the MVP phase complete, Optiscan is now poised to move into real-world validation, incorporating user feedback to refine the platform ahead of broader clinical deployment. CEO Dr Camile Farah highlighted the potential impact on rural and remote healthcare settings, where access to pathology expertise is often limited. By bridging the gap between surgery and pathology, the telepathology solution could significantly improve diagnostic speed and accuracy, ultimately enhancing patient care.

Prolucid Technologies CEO Darcy Bachert echoed this optimism, emphasizing the platform’s potential to revolutionize patient care by bringing the pathology lab to the bedside. The collaboration exemplifies how cutting-edge technology can dismantle longstanding barriers in healthcare delivery.

While regulatory approvals and commercial rollout timelines remain to be clarified, this development positions Optiscan at the forefront of digital pathology innovation, with promising implications for global healthcare systems seeking to leverage telemedicine and cloud technologies.